GlassScriptPhysician profile
Elizabeth Roberts
NPI 1588656979
$1,617.88
in general payments reported to CMS, 2019-2025
28 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $31.66 · 2021: $309 · 2022: $288 · 2023: $273 · 2024: $191 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.68 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Meditrina | $122.31 | 2025 | |
| Boston Scientific Corporation | $120.67 | 2019 | |
| Mayne Pharma Commercial LLC | $94.09 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.91 | 2021-2025 | |
| Astellas Pharma US INC | $88.43 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $80.44 | 2020-2025 | Slynd |
| Biogen, INC. | $79.03 | 2024-2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $70.86 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $64.65 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $64.43 | 2021 | |
| Hologic Sales and Service, LLC | $48.70 | 2019-2024 | Acessa Provu System, Aptima |
| Myovant Sciences INC. | $47.80 | 2021-2022 | |
| Organon LLC | $45.33 | 2024-2025 | Nexplanon |
| Therapeuticsmd, INC. | $39.04 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $20.72 | 2022 | |
| Coopersurgical, INC. | $19.72 | 2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $18.81 | 2019 | |
| Novo Nordisk INC | $18.70 | 2023 | |
| Abbott Laboratories | $18.41 | 2023 | Freestyle Libre 3 |
| Mycovia Pharmaceuticals, INC. | $18.00 | 2023 | Vivjoa |
| Amag Pharmaceuticals, INC. | $17.03 | 2020 | |
| Amgen INC. | $15.90 | 2025 | Evenity |
| Pfizer INC. | $15.76 | 2024 | |
| Agile Therapeutics, INC. | $15.61 | 2022 | |
| Shield Therapeutics INC | $13.68 | 2025 | |
| Lilly USA, LLC | $13.09 | 2024 | Zepbound |
| Ethicon US, LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.